Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-PLVAP CSR02-Fab-tissue factor

A recombinant protein consisting of an antigen-binding fragment (Fab) of CSR02, a monoclonal antibody directed against plasmalemma vesicle associated protein (PLVAP), and linked to human tissue factor (TF), with potential antineoplastic activity. Upon intra-arterial (IA) infusion of CSR02-Fab-TF, the Fab moiety targets and binds to the vascular endothelial cell specific protein PLVAP that is present on the blood vessels of hepatocellular carcinoma (HCC) but that is not present on the blood vessels of normal liver tissue. In turn, TF initiates the clotting cascade, thereby blocking blood supply from the hepatic artery to the HCC. This deprives the HCC of its blood supply and leads to tumor cell death.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:CSR02-Fab-TF
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search